IP Library Granted Patent US 7,982,056
Granted Patent B2
US 7,982,056 · App. 11/949,922 · Granted Jul 19, 2011

Substantially pure fluorescein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,982,056
App. No.
11/949,922
Granted
Jul 19, 2011
Kind
B2
Abstract

The present invention is directed to an improved process for producing substantially pure fluorescein, as well as to substantially pure fluorescein compositions prepared by the process. The invention is particularly directed to the provision of pharmaceutical compositions for use in angiography. The substantially pure fluorescein produced by the process of the present invention is low in color, low in sodium chloride content, and substantially free of pyridine.

Claims (20)

1. A composition comprising fluorescein, wherein the composition does not contain any related-substance impurity at a concentration of greater than about 0.1% by weight.

2. The composition of claim 1 wherein the composition is substantially free of pyridine.

3. The composition of claim 1 , wherein the composition does not contain any related-substance impurity at a concentration of greater than about 0.01% by weight.

4. The composition of claim 1 , wherein the total amount of related-substance impurities present in the composition is less than about 0.6% by weight.

5. The composition of claim 4 , wherein the total amount of related-substance impurities present in the composition is less than about 0.06% by weight.

6. The composition of claim 1 , wherein the fluorescein has a color number of from about 0.015 to about 0.050 AUC.

7. The composition of claim 1 , wherein the amount of residual chloride present in the composition is less than about 0.25% by weight.

8. A process for preparing fluorescein which comprises: (a) hydrolyzing diacetylfluorescein with sodium hydroxide to form fluorescein; (b) adding charcoal to the fluorescein in solution to form a fluorescein/charcoal mixture; (c) filtering the fluorescein/charcoal mixture to form a filtrate; (d) adding ethanol to the filtrate to obtain a higher proportion of ethanol than to water; (e) adjusting the pH to a level of from 1.0 to 2.5 using an acidic solution to form a precipitate; (f) filtering the solution to retain the precipitate; and (g) washing the precipitate with water and ethanol, wherein the precipitate is the fluorescein not containing any related-substance impurity at a concentration of greater than about 0.1% by weight.

9. The process of claim 8 , wherein step (e) is conducted with cooling.

10. The process of claim 8 , wherein step (e) is conducted during a period of from about 2 to about 4 hours.

11. Fluorescein prepared by the process of claim 8 wherein the fluorescein does not contain any related-substance impurity at a concentration of greater than about 0.1% by weight.

12. A method of determining the purity of a fluorescein composition which comprises: (a) obtaining a high-pressure liquid chromatogram of the composition; (b) identifying peaks in the chromatogram corresponding to related-substance impurities; and (c) taking area measurements of the peaks to determine a relative concentration thereof.

13. The method of claim 12 , wherein the peaks have relative HPLC retention times of about 0.75, 1.19, 1.23, 1.68 and 1.71.

14. A pharmaceutical composition for use in angiography, comprising fluorescein wherein the composition does not contain any related-substance impurity at a concentration of greater than about 0.1% by weight and a vehicle for injection.

15. The composition of claim 14 , wherein the composition is substantially free of pyridine.

16. The composition of claim 14 , wherein the total amount of related-substance impurities present in the composition is less than about 0.6% by weight.

17. The composition of claim 14 , wherein the composition has a color number of from about 0.015 to about 0.050 AUC.

18. The composition of claim 14 , wherein the amount of residual chloride present in the composition is less than about 0.25% by weight.

19. A composition comprising fluorescein prepared by process of claim 8 wherein the composition does not contain any related-substance impurity at a concentration of greater than about 0.1% by weight.

20. A composition comprising fluorescein prepared by deacetylation of diacetylfluorescein wherein the composition does not contain any related-substance impurity at a concentration of greater than about 0.1% by weight.

Assignments (5)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Jul 23, 2020
From: ALCON RESEARCH, LLC
To: ALCON INC.
Reel/Frame 053293/0484 →
MERGER Recorded Jul 21, 2020
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 053273/0022 →
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
MERGER Recorded Jul 21, 2008
From: ALCON MANUFACTURING, LTD.
To: ALCON RESEARCH, LTD.
Reel/Frame 021266/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2008
From: BYDLINSKI, GREGORY; HARRIS, ROBERT GREGG; SCOTT, BRITT S.
To: ALCON MANUFACTURING, LTD.
Reel/Frame 020367/0001 →